Search for optimum dose and timing of tranexamic acid administration in cardiac surgery with cardiopulmonary bypass.
Phase 4
- Conditions
- cardiac insufficiency requiring surgery (for the patients undergoing cardiac surgery with cardiopulmonary bypass)
- Registration Number
- JPRN-UMIN000003327
- Lead Sponsor
- Bellland General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Not provided
Exclusion Criteria
urgent/emergency operation, sepsis, infectious endocarditis, using IABP, renal insufficiency (Cre>2.0), active hepatitis, platerets<50000, preoperative hemostatic abnormality, continuous anticoagulant therapy, therapy with self blood, therapy with thrombin, allergy with taranexamic acid, patients recognised as inadequate for the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method blood loss in 24 hours after surgery
- Secondary Outcome Measures
Name Time Method intraoperative blood loss intraoperative transfusion blood loss in 6 hours after surgery blood loss in 12 hours after surgery total blood loss after surgery transfusion after surgery hemostatic variavles before and after culdiopulmonary bypass cytokines before and after culdiopulmonary bypass postoperative complications duration of mechanical ventilation duration of intensive care unit stay